Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
SynopsisH

Asthma drug zafirlukast (Accolate): serious hepatic events

Eric Wooltorton
CMAJ May 25, 2004 170 (11) 1668; DOI: https://doi.org/10.1503/cmaj.1040720
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: Zafirlukast is an oral leukotriene receptor antagonist used in the treatment of chronic asthma. Since the drug was first marketed in 1996, more than 100 cases of significant liver dysfunction have been reported worldwide, including 14 of liver failure.1 In some cases, no symptoms or signs of liver dysfunction were reported before the severe hepatic injury occurred. Ten cases, none fatal, have been reported in Canada. The growing number of hepatic adverse events recently prompted the drug's manufacturer, Astra Zeneca, to warn health care professionals about this rare but potentially serious adverse event.

The drug: Zafirlukast selectively competes for the leukotriene D4 and E4 receptors, both of which are implicated in the pathophysiology of asthma. The drug does not relieve acute bronchospasm, but instead it is used for the prophylaxis and chronic treatment of asthma in patients older than 12 years.2 Several drugs have been recognized to interact with zafirlukast, including warfarin, erythromycin, ASA, theophylline and terfenadine. According to the product monograph, other adverse effects associated with the drug include hypereosinophilia, hematologic abnormalities (e.g., bruising, bleeding and agranulocytosis), edema, arthralgias and myalgias.

What to do: Zafirlukast should not be prescribed to patients with hepatic dysfunction. Patients receiving the drug should be warned of these rare but potentially serious hepatic adverse effects and urged to immediately report any symptoms of concern, including pain in the right upper quadrant, nausea, vomiting, anorexia, fatigue, lethargy, flu-like symptoms, pruritus or jaundice. Serum transaminase levels should be monitored periodically and the drug stopped if hepatotoxic effects develop. In most cases, mild hepatic dysfunction seems to reverse after discontinuation of the drug, but in some cases the condition progresses to fulminant hepatitis or hepatic failure despite early detection of a problem and discontinuation of the medication. It is unclear whether this adverse effect is shared with other members of the leukotriene receptor inhibitor class, including montelukast.

Eric Wooltorton CMAJ

References

  1. 1.↵
    Important safety information regarding reports of serious hepatic events in patients receiving Accolate (zafirlukast) [Dear HealthCare Professional Letter]. Mississauga (ON): Astra Zeneca Canada Inc.; 2004 Apr 14. Available: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/accolate_2_hpc_e.html (accessed 2004 Apr 30).
  2. 2.↵
    Boulet LP, Becker A, Bérubé D, Beveridge R, Ernst P; Canadian Asthma Consensus Group. Summary of recommendations from the Canadian Asthma Consensus Report 1999. CMAJ 1999;161(11):S1-12.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 170 (11)
CMAJ
Vol. 170, Issue 11
25 May 2004
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Asthma drug zafirlukast (Accolate): serious hepatic events
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Asthma drug zafirlukast (Accolate): serious hepatic events
Eric Wooltorton
CMAJ May 2004, 170 (11) 1668; DOI: 10.1503/cmaj.1040720

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Asthma drug zafirlukast (Accolate): serious hepatic events
Eric Wooltorton
CMAJ May 2004, 170 (11) 1668; DOI: 10.1503/cmaj.1040720
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
  • The changing ecology of avian flu
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Asthma

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire